ChemoMetec raises FY 2026/27 EBITDA outlook to DKK 330-345 million

• ChemoMetec raised its 2026/27 revenue outlook to DKK 560-590 million from DKK 545-575 million.
• EBITDA guidance increased to DKK 330-345 million from DKK 300-315 million.
• Upgrade reflects stronger-than-expected instrument demand, with the NC-203 a key driver.
• Lower-than-expected costs also supported the improved forecast.
• First-quarter results are scheduled for Nov. 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ChemoMetec A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050448OMX_____CNEWS_EN_GNW1001276245_en) on October 05, 2026, and is solely responsible for the information contained therein.